Clinical Trials Browser

Phase 3 × OTHER × pembrolizumab × Clear all

NCT04777851 2026-03-09

REPLACE

Phase 3 Terminated

Gastrointestinal

Carcinoma, Hepatocellular

NCT05812807 2026-03-04

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

Phase 3 Recruiting

Anatomic Stage I Breast Cancer AJCC v8

NCT06632327 2026-03-04

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

Phase 3 Recruiting

Lung Neoplasms

NCT06661720 2026-03-04

STRIKE

Phase 3 Recruiting

Carcinoma, Renal Cell

NCT07026474 2026-03-02

RePaIr-HN

Phase 3 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT03774732 2026-02-25

NIRVANA-LUNG

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04339218 2026-01-30

CRYOMUNE

Phase 3 Recruiting

Adenocarcinoma of Lung

NCT07346053 2026-01-16

Chrono-EVP

Phase 3 Not yet recruiting

Advanced Bladder Cancer

NCT06998069 2025-12-30

Head and Neck Cancer Study Project in the Geriatric Population

Phase 3 Recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT06908993 2025-12-17

COMET

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04157985 2025-12-11

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

Phase 3 Completed

DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma

NCT07174453 2025-12-08

Trial to Evaluate irAEs With Different Standard of Care Dosing Strategies of Standard of Care Immunotherapies

Phase 3 Recruiting

Other solid neoplasm

Solid Tumor Malignancies

NCT07264075 2025-12-04

ILLUMINE

Phase 3 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT07251582 2025-11-26

LungTime-C02

Phase 3 Recruiting

Resectable Stage II-III Non-Small Cell Lung Cancer (NSCLC)

NCT06081244 2025-11-19

ADAPT-TN-III

Phase 3 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04547504 2025-09-17

PERSEE

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT07178730 2025-09-17

ADAPT-TN-IV

Phase 3 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04335669 2025-09-12

NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC

Phase 3 Active not recruiting

Pathologic Complete Response, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06606730 2025-08-26

OPT-PEMBRO

Phase 3 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05692999 2025-06-25

Pulse

Phase 3 Recruiting

Metastatic Non-squamous Lung Cancer

NCT03867175 2025-06-13

Immunotherapy With or Without SBRT in Patients With Stage IV Non-small Cell Lung Cancer

Phase 3 Completed

5 enrolled 15 charts

Lung Neoplasms

NCT06749925 2025-04-01

Clinical Trial Assessing the Efficacy and Safety of Dendritic Cell-Based Immunotherapy for Glioblastoma

Phase 3 Not yet recruiting

Glioblastoma

NCT05549037 2025-02-19

PACIFIC15

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06364631 2025-01-16

CARE1

Phase 3 Recruiting

Carcinoma, Renal Cell, Kidney Neoplasms

NCT04637594 2025-01-15

IMAGINE

Phase 3 Active not recruiting

Carcinoma, Transitional Cell

NCT04747054 2024-10-26

PembroMetaRT

Phase 3 Recruiting

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Carcinoma, Squamous Cell, Neoplasm Metastasis

NCT05055908 2024-08-02

BECOME

Phase 3 Recruiting

12,000 enrolled

Lung Neoplasms

NCT06411171 2024-05-17

Safety and Efficacy of Pembrolizumab in Combination With FLOT About Gastroesophageal Junction Cancer:

Phase 3 Not yet recruiting

Gastrointestinal

Gastroesophageal Junction Cancer

NCT05085028 2024-03-07

REFINE-Lung

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06146777 2023-11-29

Multi-classifier System for Stratifying Stage III Papillary Renal Cell Carcinoma of Receiving Adjuvant Therapy

Phase 3 Not yet recruiting

Carcinoma, Renal Cell

NCT06102395 2023-10-30

Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC

Phase 3 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT04807673 2022-06-01

KEYSTONE-002

Phase 3 Recruiting

Gastrointestinal

Esophageal Squamous Cell Carcinoma